Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $721,000.

  • Editas Medicine's Depreciation & Amortization (CF) fell 54.91% to $721,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 1.30%. This contributed to the annual value of $5.8 million for FY2024, which is 4.77% down from last year.
  • As of Q3 2025, Editas Medicine's Depreciation & Amortization (CF) stood at $721,000, which was down 60.69% from $1.8 million recorded in Q2 2025.
  • Editas Medicine's 5-year Depreciation & Amortization (CF) high stood at $1.9 million for Q1 2025, and its period low was $721,000 during Q3 2025.
  • Its 3-year average for Depreciation & Amortization (CF) is $1.5 million, with a median of $1.5 million in 2023.
  • In the last 5 years, Editas Medicine's Depreciation & Amortization (CF) spiked by 45.74% in 2021 and then crashed by 54.91% in 2025.
  • Editas Medicine's Depreciation & Amortization (CF) (Quarterly) stood at $1.6 million in 2021, then increased by 1.22% to $1.6 million in 2022, then decreased by 4.76% to $1.5 million in 2023, then dropped by 8.06% to $1.4 million in 2024, then crashed by 54.91% to $721,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $721,000 for Q3 2025, versus $1.8 million for Q2 2025 and $1.9 million for Q1 2025.